Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$67.75 USD
0.00 (0.00%)
Updated Jul 30, 2025 12:03 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BPMUF 67.75 0.00(0.00%)
Will BPMUF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BPMUF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMUF
Are Medical Stocks Lagging Basilea Pharmaceutica (BPMUF) This Year?
Best Momentum Stock to Buy for August 28th
BPMUF: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for August 28th
Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why
Is Basilea Pharmaceutica (BPMUF) Stock Outpacing Its Medical Peers This Year?